Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical GroupFRA:S2P +1.55%93 Debt-to-Equity is 0.13 as of Dec. 2025, which is 48% below its 10-year median of 0.25. GuruFocus rates FRA:S2P with a GF Score™ of 93/100 and a GF Value™ of €1.19 (Fairly Valued). Among 812 Drug Manufacturers companies, Simcere Pharmaceutical Group ranks better than 67.24% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Simcere Pharmaceutical Group's Debt-to-Equity or its related term are showing as below:
FRA:S2P'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.13 Med: 0.25 Max: 1.99
Current: 0.13
During the past 9 years, the highest Debt-to-Equity Ratio of Simcere Pharmaceutical Group was 1.99. The lowest was 0.13. And the median was 0.25.
FRA:S2P's Debt-to-Equity is ranked better than 67.24% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs FRA:S2P: 0.13
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Simcere Pharmaceutical Group Debt-to-Equity Related Terms
Simcere Pharmaceutical Group Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (FRA:S2P) has a Debt-to-Equity of 0.13 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Simcere Pharmaceutical Group and its competitors. This is 48% below median its historical median of 0.25. Over the past decade, Simcere Pharmaceutical Group's Debt-to-Equity has ranged from 0.13 to 1.99. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #266 out of 812 companies in the Drug Manufacturers industry, placing it in the top 32.8%.
Is Simcere Pharmaceutical Group's Debt-to-Equity too high?
Simcere Pharmaceutical Group's current Debt-to-Equity of 0.13 is 48% below median its 10-year median of 0.25. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 1.99. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Simcere Pharmaceutical Group's value of 0.13 is 51.9% below this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #266 out of 812 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #266 out of 812 companies for Debt-to-Equity. This puts Simcere Pharmaceutical Group in the upper half of its industry. The industry median Debt-to-Equity is 0.27. Simcere Pharmaceutical Group's value of 0.13 is 51.9% below this benchmark. Historically, Simcere Pharmaceutical Group's own Debt-to-Equity has ranged from 0.13 to 1.99 over the past decade. While the company's 10-year median is 0.25 vs. the industry median of 0.27, Simcere Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current Debt-to-Equity of 0.13 is 51.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current Debt-to-Equity is 0.13, which is 48% below median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (FRA:S2P) is currently considered Fairly Valued. The stock's GF Value™ is €1.19, compared to a current price of €1.31 — trading 10.1% above its estimated fair value. The current Debt-to-Equity is 0.13, which is 48% below median its 10-year median of 0.25 and 51.9% below the Drug Manufacturers industry median of 0.27. Simcere Pharmaceutical Group's overall GF Score™ is 93/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Simcere Pharmaceutical Group (FRA:S2P), the current Debt-to-Equity is 0.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (FRA:S2P) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.31 is trading 10.1% above its estimated GF Value™ of €1.19.
GuruFocus considers Simcere Pharmaceutical Group to be Fairly Valued.
Key valuation signals for FRA:S2P:
Debt-to-Equity: 0.13 (48% below median its 10-year median of 0.25)
GF Value™: €1.19 vs. price of €1.31 (10.1% above fair value)
Industry Position: 51.9% below the Drug Manufacturers median (#266 of 812)
No single metric tells the full story. See the FRA:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
93GF Score
Get the complete analysis for FRA:S2P
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S2P has been successfully added to your 
